Real-world research on beta-blocker usage trends in China and safety exploration based on the FDA Adverse Event Reporting System (FAERS).

Autor: Yan Y; Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, P. R. China.; Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Capital Medical University, Beijing, 100045, P. R. China., An W; Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, P. R. China.; Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Capital Medical University, Beijing, 100045, P. R. China., Mei S; Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, P. R. China.; Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Capital Medical University, Beijing, 100045, P. R. China., Zhu Q; Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, P. R. China., Li C; Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, P. R. China.; Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Capital Medical University, Beijing, 100045, P. R. China., Yang L; Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, P. R. China. 0530yangli@163.com.; Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Capital Medical University, Beijing, 100045, P. R. China. 0530yangli@163.com., Zhao Z; Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, P. R. China. 1022zzg@sina.com.; Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Capital Medical University, Beijing, 100045, P. R. China. 1022zzg@sina.com., Huo J; Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan West Road, Fengtai District, Beijing, P. R. China. gaoshan-523@163.com.; Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Capital Medical University, Beijing, 100045, P. R. China. gaoshan-523@163.com.
Jazyk: angličtina
Zdroj: BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2024 Nov 14; Vol. 25 (1), pp. 86. Date of Electronic Publication: 2024 Nov 14.
DOI: 10.1186/s40360-024-00815-w
Abstrakt: Background: Beta-blockers are widely used, with continuously updated clinical recommendations. However, their application faces challenges in personalized treatment and safety. The study aimed to investigate the frequency and patterns of prescribing beta-blockers in China and to explore potential adverse event risk signals associated with beta-blockers, providing reference for rational medication use in clinical settings.
Methods: Prescription data for beta-blockers from January 2018 to June 2023 were extracted through the Hospital Prescription Analysis Collaborative Project in China to analyze clinical usage trends. While adverse drug reaction reports for beta-blockers were obtained from the FDA Adverse Event Reporting System (FAERS) database. The classification and standardization of adverse drug event (ADE) reports were based on the preferred terms (PT) and corresponding system organ classes (SOC) from the Medical Dictionary for Regulatory Activities (MedDRA). Signal detection utilized a proportion imbalance method.
Results: In clinical practice, metoprolol dominated beta-blocker prescriptions in China, accounting for 62.2%. Beta-blockers were primarily prescribed to the elderly (65.7%) and male patients (57.0%). However, off-label use of beta-blockers was relatively widespread. For instance, sotalol was prescribed for hypertension at 18.25%, while esmolol was used for angina and heart failure at rates of 12.94% and 14.98%, respectively. In addition, we identified newly discovered adverse reactions associated with beta-blockers, such as BRASH syndrome (metoprolol: n = 186, ROR = 391.285; carvedilol: n = 72, ROR = 256.459), acute kidney injury (bisoprolol: n = 247, ROR = 5.641), premature baby (labetalol: n = 110, ROR = 91.385), and sleep disorder (propranolol: n = 254, ROR = 10.98).
Conclusions: Metoprolol led the beta-blocker market in China. Attention was warranted regarding the newly discovered adverse reactions, such as the risk of acute kidney injury with bisoprolol and the potential for BRASH syndrome with metoprolol and carvedilol.
Competing Interests: Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: